Summary: This study presents a case of a critically ill 14-year-old girl with Epstein-Barr virus-related hemophagocytic lymphohistiocytosis who was treated with Ruxolitinib in conjunction with the HLH-94 protocol.
Summary: This study compared the effects of glucocorticoids and tocilizumab versus tocilizumab alone. Researchers evaluated mortality rates, patients requiring intubation and combined amongst 92 patients who experienced a cytokine storm syndrome (CSS) associated to COVID-19.
Summary: This study evaluated the effectiveness of tocilizumab in patients with COVID-19 (a mild to severe respiratory illness that is caused by a coronavirus) infection-induced cytokine release syndrome (large, rapid release of cytokines into the blood from immune cells affected by the immunotherapy; CRS).
Summary: In this study, researchers evaluated the effects of using ruxolitinib to treat acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Summary: This study evaluated the reduced-intensity conditioning regimen in allogeneic hematopoietic cell transplantation (HCT) for adult patients with hemophagocytic lymphohistiocytosis (too many immune cells; HLH).